ReviewEngineering biology2022
The roadmap of bioeconomy in China.
Review in Engineering biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Beyond petrochemicals: challenges and opportunities in industrial-scale biomanufacturing.Nature communications · 2026Review
- China's biosafety/biosecurity governance: evolution, challenges, and architecture design.Frontiers of medicine · 2025Article
- Agricultural biotechnology in China: product development, commercialization, and perspectives.aBIOTECH · 2025Review
- Alternative Splicing in Tumorigenesis and Cancer Therapy.Biomolecules · 2025Review
- The Developing Standards Landscape for Cell and Gene Therapies.Advances in experimental medicine and biology · 2025Review
- Exploring the Promoter Generation and Prediction ofInternational journal of molecular sciences · 2024Article
- Synthetic biology in plants.Plant biotechnology (Tokyo, Japan) · 2024Article
- Cell-Free Synthesis: Expediting Biomanufacturing of Chemical and Biological Molecules.Molecules (Basel, Switzerland) · 2024Review
- The worsening divergence of biotechnology: the importance of risk culture.Frontiers in bioengineering and biotechnology · 2023Article
- The roadmap of bioeconomy in China.Engineering biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The bioeconomy drives the development of life science and biotechnology as a blueprint for the future development of human society, and offers a cross-cutting perspective on the societal transformation towards long-term sustainability and the transition away from the non-renewable economy. Moreover, the sustainable bioeconomy strategies are consistent with the United Nation's (UN) Sustainable Development Goals (SDG) and are becoming the centre of the achievement for SDG. The Chinese '14th Five-Year Plan for Bioeconomy Development' (2021-2025), including the development goals of China's bioeconomy containing biomedicine, agriculture, bio-manufacturing and bio-security as a strategic priority, is discussed. The plan offers three pathways to improve bioeconomy, including technological innovation, industrialisation and policy supports. Finally, it concludes China's first bioeconomy development plan as a success, suggesting the key role of industrial biotechnology in bioeconomy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.